Health Care [ 10/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 29, 26 | 1.99 Decreased by -42.15% | 1.76 Increased by +13.07% |
| Oct 29, 25 | 4.81 Increased by +17.89% | 3.85 Increased by +24.94% |
| Jul 31, 25 | 5.47 Increased by +3.60% | 3.88 Increased by +40.98% |
| May 1, 25 | 3.02 Decreased by -17.71% | 2.95 Increased by +2.37% |
| Feb 12, 25 | 3.44 Increased by +4.24% | 3.36 Increased by +2.38% |
| Oct 30, 24 | 4.08 Decreased by -6.42% | 3.79 Increased by +7.65% |
| Aug 1, 24 | 5.28 Increased by +31.34% | 4.03 Increased by +31.02% |
| Apr 24, 24 | 3.67 Increased by +7.94% | 3.45 Increased by +6.38% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 2.28 B Decreased by -7.15% | -48.41 M Decreased by -118.15% | Decreased by -2.12% Decreased by -119.55% |
| Sep 30, 25 | 2.45 B Decreased by -0.45% | 466.50 M Increased by +20.08% | Increased by +19.00% Increased by +20.62% |
| Jun 30, 25 | 2.65 B Increased by +7.33% | 634.80 M Increased by +8.77% | Increased by +24.00% Increased by +1.35% |
| Mar 31, 25 | 2.43 B Increased by +6.13% | 240.50 M Decreased by -38.87% | Increased by +9.89% Decreased by -42.40% |
| Dec 31, 24 | 2.45 B Increased by +2.87% | 266.70 M Increased by +6.81% | Increased by +10.86% Increased by +3.83% |
| Sep 30, 24 | 2.47 B Decreased by -2.55% | 388.50 M Increased by +670.48% | Increased by +15.76% Increased by +685.41% |
| Jun 30, 24 | 2.46 B Increased by +0.36% | 583.60 M Decreased by -1.35% | Increased by +23.68% Decreased by -1.71% |
| Mar 31, 24 | 2.29 B Decreased by -7.00% | 393.40 M Increased by +1.42% | Increased by +17.18% Increased by +9.06% |